Publications by authors named "Craig La Force"

Claim this Profile
A
As-Needed Albuterol-Budesonide in Mild Asthma. Reply.
Craig LaForce, Alberto Papi, Leonard B Bacharier,

N Engl J Med· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
As-Needed Albuterol-Budesonide in Mild Asthma.
Craig LaForce, Frank Albers, Anna Danilewicz, Allison Jeynes-Ellis, Monica Kraft

N Engl J Med· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Fully Decentralized Randomized Controlled Study of As-Needed Albuterol-Budesonide Fixed-Dose Inhaler in Mild Asthma: The BATURA Study Design.
Craig LaForce, Frank C Albers, Mark Cooper, Anna Danilewicz, Lynn Dunsire

J Asthma Allergy· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Albuterol/budesonide for the treatment of exercise-induced bronchoconstriction in patients with asthma: The TYREE study.
Craig LaForce, Bradley E Chipps, Frank C Albers, Laurence Reilly, Eva Johnsson

Ann Allergy Asthma Immunol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose-Ranging and Cumulative Dose Studies of Albuterol Sulfate MDI in Co-Suspension Delivery™ Technology (AS MDI; PT007) in Patients with Asthma: the ASPEN and ANTORA Trials.
Christy Cappelletti, Andrea Maes, Kimberly Rossman, Michael Gillen, Craig LaForce

Clin Drug Investig· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Step-Up Therapy in Black Children and Adults with Poorly Controlled Asthma.
Michael E Wechsler, Stanley J Szefler, Victor E Ortega, Jacqueline A Pongracic, Vernon Chinchilli, Craig F LaForce

N Engl J Med· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mometasone or Tiotropium in Mild Asthma with a Low Sputum Eosinophil Level.
Stephen C Lazarus, Jerry A Krishnan, Tonya S King, Jason E Lang, Kathryn V Blake, Craig LaForce

N Engl J Med· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Measurement of exhaled nitric oxide in young children.
Kathleen Rickard, Margot MacDonald-Berko, Robert Anolik, Neal Jain, Craig La Force

Ann Allergy Asthma Immunol· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety of tiotropium/olodaterol Respimat in patients with moderate-to-very severe COPD and renal impairment in the TONADO studies.
Craig LaForce, Eric Derom, Ulrich Bothner, Isabel M Kloer, Matthias Trampisch

Int J Chron Obstruct Pulmon Dis· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of twice-daily glycopyrrolate in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation: the GEM1 study.
Craig LaForce, Gregory Feldman, Selwyn Spangenthal, Joerg H Eckert, Michelle Henley

Int J Chron Obstruct Pulmon Dis· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Gary T Ferguson, J Mark FitzGerald, Eugene R Bleecker, Michel Laviolette, David Bernstein, Craig LaForce

Lancet Respir Med· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized, placebo-controlled study of cetirizine and loratadine in children with seasonal allergic rhinitis.
Anjuli S Nayak, William E Berger, Craig F LaForce, Eduardo R Urdaneta, Mitesh K Patel

Allergy Asthma Proc· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized study of BI 671800, a CRTH2 antagonist, as add-on therapy in poorly controlled asthma.
David Miller, Chester Wood, Eric Bateman, Craig LaForce, Jon Blatchford

Allergy Asthma Proc· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Albuterol multidose dry powder inhaler efficacy and safety versus placebo in children with asthma.
Craig LaForce, Herminia Taveras, Harald Iverson, Paul Shore

Allergy Asthma Proc· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomised, double-blind, placebo-controlled crossover study to investigate different dosing regimens of olodaterol delivered via Respimat® in patients with moderate to severe persistent asthma.
Kai-Michael Beeh, Craig LaForce, Martina Gahlemann, Arne Wenz, Robert Toorawa

Respir Res· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of cetirizine on symptom severity and quality of life in perennial allergic rhinitis.
David P Skoner, Craig F LaForce, Robert A Nathan, Eduardo R Urdaneta, Michael A Zielinski

Allergy Asthma Proc· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Once-daily indacaterol 75 μg in moderate- to-severe COPD: results of a Phase IV study assessing time until patients' perceived onset of effect.
Thomas M Siler, Craig F LaForce, Farid Kianifard, James Williams, Selwyn Spangenthal

Int J Chron Obstruct Pulmon Dis· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of exhaled nitric oxide measurements on treatment decisions in an asthma specialty clinic.
Craig LaForce, Elizabeth Brooks, Nancy Herje, Paul Dorinsky, Kathy Rickard

Ann Allergy Asthma Immunol· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The 24-h FEV1 time profile of olodaterol once daily via Respimat® and formoterol twice daily via Aerolizer® in patients with GOLD 2-4 COPD: results from two 6-week crossover studies.
Gregory J Feldman, Jonathan A Bernstein, Alan Hamilton, Michael C Nivens, Lawrence Korducki, Craig LaForce

Springerplus· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of once-daily fluticasone furoate/vilanterol (100/25 mcg) versus twice-daily fluticasone propionate/salmeterol (250/50 mcg) in COPD patients.
Mark T Dransfield, Gregory Feldman, Phillip Korenblat, Craig F LaForce, Nicholas Locantore

Respir Med· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of vitamin D3 on asthma treatment failures in adults with symptomatic asthma and lower vitamin D levels: the VIDA randomized clinical trial.
Mario Castro, Tonya S King, Susan J Kunselman, Michael D Cabana, Loren Denlinger, Craig LaForce

JAMA· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Ocular safety of fluticasone furoate nasal spray in patients with perennial allergic rhinitis: a 2-year study.
Craig LaForce, Glen E Journeay, S David Miller, Mary Jane Silvey, Wei Wu

Ann Allergy Asthma Immunol· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fluticasone/Formoterol combination therapy compared with monotherapy in adolescent and adult patients with mild to moderate asthma.
David S Pearlman, Craig F LaForce, Kirsten Kaiser

Clin Ther· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized, double-blind, placebo-controlled, safety and immunogenicity study of 4 formulations of Anthrax Vaccine Adsorbed plus CPG 7909 (AV7909) in healthy adult volunteers.
Robert J Hopkins, Nancy F Daczkowski, Paulina E Kaptur, Derek Muse, Eric Sheldon, Craig LaForce

Vaccine· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) in the treatment of seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial of efficacy and safety.
Eli O Meltzer, Craig LaForce, Paul Ratner, David Price, David Ginsberg

Allergy Asthma Proc· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis